Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.12
+0.14 (1.56%)
At close: Mar 9, 2026, 4:00 PM EDT
10.75
+1.63 (17.87%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Zevra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 106.47 | 23.61 | 27.46 | 10.16 | 28.65 | Upgrade
|
| Revenue Growth (YoY) | 350.92% | -14.02% | 170.26% | -64.53% | 115.61% | Upgrade
|
| Cost of Revenue | 16.48 | 7.42 | 2.17 | 0.22 | 2.06 | Upgrade
|
| Gross Profit | 89.99 | 16.2 | 25.29 | 9.94 | 26.59 | Upgrade
|
| Selling, General & Admin | 77.62 | 54.92 | 35.09 | 15.61 | 9.23 | Upgrade
|
| Research & Development | 12.74 | 42.04 | 39.03 | 19.23 | 9.64 | Upgrade
|
| Amortization of Goodwill & Intangibles | 3.86 | 6.24 | 0.77 | - | - | Upgrade
|
| Operating Expenses | 94.22 | 103.2 | 74.89 | 34.84 | 18.86 | Upgrade
|
| Operating Income | -4.23 | -87 | -49.6 | -24.9 | 7.73 | Upgrade
|
| Interest Expense | -7.98 | -7.35 | -1.5 | -0.34 | -0.38 | Upgrade
|
| Interest & Investment Income | - | 2.18 | 4.54 | 1.51 | 0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.12 | 2.06 | -0.1 | 15.16 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -3.09 | -90.12 | -46.66 | -8.57 | 7.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.15 | -0.02 | 0.61 | -0.58 | -0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 148.33 | - | - | - | - | Upgrade
|
| Asset Writedown | -58.71 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -16.1 | Upgrade
|
| Pretax Income | 86.68 | -90.14 | -46.05 | -26.81 | -8.52 | Upgrade
|
| Income Tax Expense | 3.45 | 15.37 | - | -0.03 | 0.03 | Upgrade
|
| Net Income | 83.23 | -105.51 | -46.05 | -26.77 | -8.56 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 54.34 | Upgrade
|
| Net Income to Common | 83.23 | -105.51 | -46.05 | -26.77 | -62.9 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 46 | 35 | 34 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 46 | 35 | 34 | 30 | Upgrade
|
| Shares Change (YoY) | 23.81% | 30.46% | 2.79% | 15.87% | 647.72% | Upgrade
|
| EPS (Basic) | 1.50 | -2.28 | -1.30 | -0.78 | -2.11 | Upgrade
|
| EPS (Diluted) | 1.35 | -2.28 | -1.30 | -0.78 | -2.11 | Upgrade
|
| Free Cash Flow | -2.43 | -69.67 | -33.83 | -18.81 | 10.34 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -1.51 | -0.95 | -0.55 | 0.35 | Upgrade
|
| Gross Margin | 84.52% | 68.59% | 92.09% | 97.81% | 92.81% | Upgrade
|
| Operating Margin | -3.98% | -368.47% | -180.63% | -245.07% | 26.98% | Upgrade
|
| Profit Margin | 78.17% | -446.85% | -167.69% | -263.48% | -219.54% | Upgrade
|
| Free Cash Flow Margin | -2.28% | -295.04% | -123.20% | -185.12% | 36.08% | Upgrade
|
| EBITDA | -0.18 | -80.61 | -48.6 | -23.96 | 7.99 | Upgrade
|
| EBITDA Margin | -0.17% | - | -176.97% | -235.78% | 27.87% | Upgrade
|
| D&A For EBITDA | 4.05 | 6.39 | 1.01 | 0.94 | 0.26 | Upgrade
|
| EBIT | -4.23 | -87 | -49.6 | -24.9 | 7.73 | Upgrade
|
| EBIT Margin | -3.98% | - | -180.63% | -245.07% | 26.98% | Upgrade
|
| Effective Tax Rate | 3.98% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.